This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Medicines Discovery Catapult | |
|---|---|
| Name | Medicines Discovery Catapult |
| Formation | 2015 |
| Type | Research and development organisation |
| Headquarters | Newcastle upon Tyne, England |
| Region served | United Kingdom |
| Parent organization | Innovate UK |
Medicines Discovery Catapult Medicines Discovery Catapult is a translational research and development organisation focused on accelerating drug discovery and early-stage medicines development. It operates as a technology and knowledge bridge between academic institutions such as University of Oxford, University of Cambridge, and Imperial College London and industry partners including GlaxoSmithKline, AstraZeneca, and Pfizer. The organisation engages with funding bodies like UK Research and Innovation, policy institutions such as Department for Business and Trade, and regional development agencies including Newcastle City Council.
Established in 2015, the organisation formed as part of a network of technology and innovation centres modelled after entities like Catapult centres and influenced by programmes run by Innovate UK and Research Councils UK. Early milestones included collaborations with pharmaceutical firms such as Eli Lilly and Company and biotechnology companies including Genentech, and academic consortia from University College London and University of Manchester. Key initiatives paralleled efforts seen at institutions like Wellcome Trust and Medical Research Council, and expanded amid strategic reviews by 10 Downing Street and policy reports from House of Commons Science and Technology Committee.
The organisation's mission emphasises de-risking translational projects, enabling SMEs and spin-outs such as those from Oxford Nanopore Technologies and Autolus Therapeutics to progress molecules toward clinical proof-of-concept. Objectives align with national innovation aims set by UK Research and Innovation and sector roadmaps from Association of the British Pharmaceutical Industry and include capability development akin to programmes at European Molecular Biology Laboratory and National Institute for Health and Care Research.
Based in specialised facilities in Newcastle upon Tyne, the organisation hosts platforms for medicinal chemistry, high-throughput screening, and assay development comparable to amenities at Francis Crick Institute and Babraham Institute. Capabilities include structural biology resources paralleling Diamond Light Source, biophysical characterisation similar to EMBL-EBI, and in vitro pharmacology suites akin to those at Glasgow University. The site infrastructure supports workflows used by companies like Roche and Novartis for lead optimisation and ADME profiling.
Programmes target small-molecule discovery, biologics enablement, and target validation with services offered to academic spin-outs such as Oxbridge spin-outs and regionally based SMEs supported by Northern Powerhouse. Services include hit identification, medicinal chemistry, and translational assays used by partners like Bayer and Sanofi. Projects often mirror consortia approaches seen in initiatives led by Innovative Medicines Initiative and involve technologies employed by groups such as CRUK (Cancer Research UK) and Alzheimer's Research UK.
The organisation maintains collaborative agreements with universities including Newcastle University, University of Edinburgh, and University of Strathclyde, and industry partners such as Shire Pharmaceuticals and Boehringer Ingelheim. It participates in multi-stakeholder networks alongside National Health Service bodies, regional bodies like North of Tyne Combined Authority, and international programmes including those run by European Commission and Horizon 2020. Collaborative models reflect alliances similar to Medicines Discovery Catapult-adjacent centres such as Precision Medicine Catapult and High Value Manufacturing Catapult.
Primary funding streams originate from public innovation investors such as Innovate UK and project grants from organisations like Wellcome Trust and European Investment Bank-backed schemes. Governance structures align with non-executive oversight seen in entities overseen by UK Research and Innovation and board compositions that include leaders from Life Sciences Industrial Strategy-related organisations and corporate partners such as Johnson & Johnson. Financial models incorporate commercial service revenues from contracts with companies like Charles River Laboratories and collaborative grant funding mechanisms common to Academic Health Science Networks.
The organisation has been credited with enabling translational milestones for SMEs and academic teams that resulted in licensing deals reminiscent of transactions involving Astex Pharmaceuticals and C4X Discovery. Recognition includes mention in policy reports from House of Lords Science and Technology Committee and citations in strategy documents produced by Office for Life Sciences and British Business Bank. Its contributions to regional innovation ecosystems echo outcomes associated with the Northern Accelerator initiative and broader UK life sciences growth strategies.
Category:Biotechnology companies of the United Kingdom Category:Organisations based in Newcastle upon Tyne